NAD+ injections: what the research says. | Reddit

NAD+ is a coenzyme present in every living cell, where it carries electrons through the reactions that produce ATP and is consumed as a substrate by enzymes governing DNA repair and cellular stress signalling. An injection is a delivery route, not a different molecule. The route exists because of bioavailability: parenteral NAD+ is given on the premise that it bypasses digestion, and that premise has been assumed far more often than it has been tested.

No. Peptides are short chains of amino acids joined by peptide bonds. NAD+ is a dinucleotide: two nucleotides, one carrying nicotinamide and one carrying adenine, linked through a pair of phosphate groups. The two get filed together because both are injectable, both are compounded, and both are sold into the same wellness category. Chemically they share nothing, which means no peptide research transfers to NAD+ and none of the NAD+ literature says anything about peptides.

Two jobs at once. As a redox cofactor, NAD+ cycles between its oxidised (NAD+) and reduced (NADH) forms, ferrying electrons through the mitochondrial electron transport chain that generates most cellular ATP. Separately, it is consumed as a substrate by three enzyme families, which is why reviews describe NAD+ availability as a control point rather than a fuel gauge.

Age-associated changes in NAD+ metabolism have been measured directly in human tissue samples (Massudi et al., PLoS One, 2012). Preclinical work points at consumption rather than failing synthesis: CD38 expression rises with age and drains the pool through a SIRT3-dependent mechanism (Camacho-Pereira et al., Cell Metabolism, 2016, preclinical). A 2025 Nature Metabolism review is more cautious about the human picture, noting that a consistent age-related decline in NAD+ has been observed in only a limited number of human studies.

There are two answers, and the distance between them is the whole story. What clinics and patients report is subjective: energy, focus, recovery. What controlled trials have measured is narrower, mostly blood NAD+ levels, and mostly using oral precursors. A 2024 systematic review set out to establish whether NAD+ and NADH are safe and effective as human supplements. A 2025 Nature Metabolism review of the same field concluded that while preclinical work supports NAD+ repletion as a strategy, human clinical trials have shown limited efficacy.

The scale is worth knowing. A 2026 PRISMA-guided systematic review screened preclinical and clinical NAD+ intervention studies published between January 2010 and October 2025 and identified 113 eligible studies, of which 33 were human intervention studies. A 2023 review in Science Advances examined the 25 published human nicotinamide riboside studies specifically to separate the supported claims from the poorly founded ones.

No trial in the set below showed that injected NAD+ outperforms an oral precursor on any clinical endpoint, that raising NAD+ slows human aging, that a subjective energy effect survives placebo control, or that a measured benefit is specific to the injected route.

Almost the entire controlled human record uses oral precursors. Two entries below involve a needle, and only one of those involves NAD+ itself. That imbalance is the single most useful thing to know before reading any marketing page about drips.

Two further randomised trials sit outside the table because their populations are narrow: a double-blind crossover trial of nicotinamide riboside in patients with Werner syndrome, a hereditary premature-aging condition in which NAD+ depletion has been reported (human, Aging Cell, 2025), and a randomised crossover trial of coenzyme Q10 and nicotinamide riboside in 25 patients with chronic kidney disease (human, JCI Insight, 2023). Both illustrate the pattern: the compound under test is a precursor, the endpoint is metabolic, and the population is a disease group rather than a healthy adult seeking more energy.

NR and NMN are precursors: the body converts them into NAD+ through its own salvage pathway. Injected NAD+ is the finished coenzyme. The commercially convenient assumption is that delivering the finished molecule must be superior. No trial in this evidence base tests that assumption head to head.

There is no trial-established dose for injected NAD+. The milligram figures circulating for IV drips and subcutaneous protocols come from clinic practice, not from dose-finding studies. The doses that do carry controlled human data are all oral precursor doses: 100 to 1,000 mg per day of NR, and 300 to 900 mg per day of NMN. Those figures were selected to move a blood biomarker, which is not the same thing as a dose selected to produce a result you can feel.

Three routes are in commercial use, and the published literature says very little that compares them. A 2026 retrospective report in Frontiers in Aging set out to compare intravenous NAD+ against intravenous NR in a real-world setting precisely because clinical and wellness settings increasingly provide both despite limited evaluation of safety and effectiveness.

Trial-grade safety data on injected NAD+ is thin. What exists is narrow in scope and reassuring within that scope, and it should not be read as a safety profile for a long-running infusion protocol. Absence of documented harm is not the same as documented safety.

There is no published contraindication list for injectable NAD+, because there is no approved labelling to carry one. What stands in its place is a prescriber reviewing your history before anything is dispensed.

Blood levels and felt effects are two different questions with two different answers. The biomarker moves quickly: a single oral dose of NR raised blood NAD+ by as much as 2.7-fold in a one-person pilot, with dose-dependent increases across 100, 300 and 1,000 mg in the first clinical trial of the compound (Nature Communications, 2016). No controlled trial establishes a timeline for a subjective effect from injected NAD+.

No. Injectable NAD+ is not an FDA-approved drug for any indication, so there is no approved dose, no approved indication, and no approved labelling. It is prepared for an individual patient by a licensed 503A compounding pharmacy in the USA against a prescription. Oral NR and NMN sit in a different regulatory category entirely: they are sold as dietary supplements, which carry a different evidence standard and are not pharmaceutical products.

The same handful of questions recurs, and most of them have short honest answers that vendor pages tend to avoid giving.

Through a licensed clinician who reviews your history and decides whether NAD+ is appropriate for you. The difference between that and a drip bar is not the molecule. It is who is accountable for the dose, where the vial was compounded, and whether anyone is watching what happens next.